Our lab has previously established that the Src family kinase Fyn is controlled by the elevated ROS levels in CML [37], and overexpression of Fyn has been suggested as a mediator of imatinib resistance in CML [38–40]. Here, FYN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.